Drimva

Novartis

Senior Principal Scientist/Principal Scientist, Immune Engagers

$126K–$246K

Cambridge (USA) · Principal · Full-time · Posted Oct 26, 2026

Experience
5+ years of relevant research and/or industry experience with a PhD; or 10+ years of relevant industry experience with an MS.
Education
PhD in cancer biology, immunology, or a related discipline; or MS.

About the job

Leads biology and drug-discovery programs for immune cell engagers and multispecific immune modulators, advancing cancer therapies from target validation toward clinical development.

What you'll do

  • Identify and validate tumor-targeting strategies and lead biology strategy and execution for multidisciplinary discovery programs.
  • Design and interpret mechanistic studies, integrate cross-functional perspectives, and present evidence-based recommendations at governance reviews.
  • Lead and develop scientists, build collaborations, and contribute to immune-engager strategy and modality innovation.

What they ask for

  • PhD in cancer biology, immunology, or a related discipline with 5+ years of relevant research and/or industry experience; or MS with 10+ years of relevant industry experience.
  • Expertise in cancer biology and/or immunology, including tumor immunology, T-cell or myeloid-cell biology, and immune suppression in the tumor microenvironment.
  • Proficiency in immune-cell functional assays and complex immunophenotyping, including in vitro and ex vivo assays and multiparameter flow cytometry.
  • Experience in antibody, multispecific biologic, and/or immune-engager discovery within cross-functional teams; strong research publication track record.

Nice to have

  • Leadership in T-cell or myeloid cell-engager discovery from target validation through IND-enabling or early clinical activities.
  • Project-team leadership, next-generation engager innovation, and mentoring experience.

Pay

$126,000 - $234,000 per year (base salary); $132,300 - $245,700 per year (base salary)

Tools

multiparameter flow cytometry

Model-written summary · the original posting is authoritative

First seen Oct 28, 2026 · Last verified Nov 6, 2026 (UTC)